The efficacy of mirtazapine in agitated patients with Alzheimer's disease: A 12-week open-label pilot study

Neuropsychiatric Disease and Treatment

Volumn 4, Issue 5, 2008, Pages 963-966

  Cakir, Sibel ^a   Kulaksizoglu, Isin Baral ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Agitation; Alzheimer's disease; Mirtazapine; Open label; Safety; Treatment

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; MIRTAZAPINE; NEUROLEPTIC AGENT;

ADULT; AGED; AGITATION; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR DISORDER; BLOOD CHEMISTRY; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE ASSOCIATION; DISEASE DURATION; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HUMAN; MALE; MENTAL DETERIORATION; NEUROPSYCHOLOGICAL TEST; OPEN STUDY; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PILOT STUDY; RISK REDUCTION; SEDATION; SIDE EFFECT; WEIGHT GAIN;

EID: 56849096777     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: 10.2147/ndt.s3201     Document Type: Article

References (20)

1. Ballard CG, Margallo-Lana M, Fossey J, et al. 2001. A 1-year follow-up study of behavioral and psychological symptoms in dementia among people in care environments. J Clin Psychiatry, 62:631-6.
2. Ballard C, Walte J. 2006. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev, 25:CD003476.
3. Cohen-Mansfield J. 1986. A gitated behaviors in the elderly. II. Preliminary results in the cognitively deteriorated. J Am Geriatr Soc, 34:722-7.
4. Cohen-Mansfield J. 1996. Assessment of agitation. Int Psychogeriatr, 8:233-45.
5. Cohen-Mansfield J, Garfinkel D, Lipson S. 2000. Melatonin for treatment ofsundowning in elderly persons with dementia - a preliminary study. Arch Gerontol Geriatr, 31:65-76.
6. Gardner ME, Malone DC, Sey M, et al. 2004. Mirtazapine is associated with less anxiolytic use among elderly depressed patients in long-term care facilities. J Am Med Dir Assoc, 5:101-6.
7. Golombok S, Moodley P, Lader M. 1988. Cognitive impairment in long-term benzodiazepine users. Psychol Med, 19:365-74.
8. Herrmann N, Lanctôt KL, Rothenburg LS, et al. 2007. A placebo-controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dement Geriatr Cogn Disord, 23:116-9.
9. Howard RJ, Juszczak E, Ballard CG, et al; CALM-AD Trial Group. 2007. Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med, 357:1382-92.
10. Nelson JC, Hollander SB, Betzel J, et al. 2006. Mirtazapine orally disintegrating tablets in depressed nursing home residents 85 years of age and older. Int J Geriatr Psychiatry, 21:999-901.
11. Pollock BG, Mulsant BH, Sweet R, et al. 1997. An open pilot study of citalopram for behavioral disturbances of dementia. Plasma levels and real-time observations. Am J Geriatr Psychiatry, 5:70-8.
12. Ramadan FH, Naughton BJ. 1999. Paroxetine for verbal agitation. Ann Long Term Care, 7:282-86.
13. Ray WA, Griffin MR, Downey W. 1989. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA, 262:3303-7.
14. Roose SP, Nelson JC, Salzman C, et al; Mirtazapine in the Nursing Home Study Group. 2003. Open-label study of mirtazapine orally disintegrating tablets in depressed patients in the nursing home. Curr Med Res Opin, 19:737-46.
15. Schatzberg AF, Kremer C, Rodrigues HE, et al; Mirtazapine vs Paroxetine Study Group. 2002. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry, 10:541-50.
16. Schmid DA, WIchnIak A, Uhr M, et al. 2006. Changes of sleep architecture, spectral composition of sleep EEG, the nocturnal secretion of cortisol, ACTH, GH, prolactin, melatonin, ghrelin, and leptin, and the DEX-CRH test in depressed patients during treatment with mirtazapine. Neuropsychopharmacology, 31:832-44.
17. Schneider LS, Dagerman KS, Insel P. 2005. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA, 294:1934-43.
18. Schneider LS, Dagerman K, Insel PS. 2006a. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry, 14:191-210.
19. Schneider LS, Tariot PN, Dagerman KS, et al; CATIE-AD Study Group. 2006b. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med, 355:1525-38.
20. Tractenberg RE, Weiner MF, Thal LJ. 2002. Estimating the prevalence of agitation in community-dwelling persons with Alzheimer's disease. J Neuropsychiatry Clin Neurosci, 14:11-8.